This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oct. 31, 2013 /PRNewswire/ --
Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on
Thursday, November 14, 2013, at
4:30 p.m. Eastern time to discuss results for the third quarter ended
September 30, 2013. Financial results will be issued in a press release prior to the call.
Vermillion's President and CEO
Thomas McLain will host the call, followed by a question and answer period.
Thursday, November 14, 2013Time:
4:30 p.m. Eastern time (
3:30 p.m. Central time)Dial-in number: 1-800-734-8507 International dial-in number: 1-212- 231-2918Conference ID: 21676489 Webcast:
The conference call will be webcast live and available for replay via the investor section of the company's website at
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A replay of the call will be available approximately two hours after the call through
November 28, 2013.
Toll-free replay number: 1-800-633-8284International replay number: 1-402-977-9140Replay ID: 21676489
About VermillionVermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.
The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit
Investor Relations Contact:Liolios Group, Inc.
Ron Both Tel 1-949-574-3860
SOURCE Vermillion, Inc.